stoxline Quote Chart Rank Option Currency Glossary
  
Addex Therapeutics Ltd (ADXN)
9.67  -0.63 (-6.12%)    02-23 14:24
Open: 10.375
High: 10.3988
Volume: 9,151
  
Pre. Close: 10.3
Low: 9.67
Market Cap: 14(M)
Technical analysis
2024-02-23 4:34:47 PM
Short term     
Mid term     
Targets 6-month :  12.62 1-year :  15.76
Resists First :  10.8 Second :  13.5
Pivot price 10.39
Supports First :  6.44 Second :  5.36
MAs MA(5) :  10.13 MA(20) :  10.65
MA(100) :  7.32 MA(250) :  11.78
MACD MACD :  0.4 Signal :  0.7
%K %D K(14,3) :  33.3 D(3) :  28.8
RSI RSI(14): 49.9
52-week High :  45.59 Low :  5
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ ADXN ] has closed above bottom band by 7.0%. Bollinger Bands are 35.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 10.41 - 10.47 10.47 - 10.52
Low: 9.54 - 9.6 9.6 - 9.66
Close: 9.58 - 9.68 9.68 - 9.77
Company Description

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot–Marie–Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

Headline News

Wed, 31 Jan 2024
Addex Therapeutics initiates at-the-market offering program By Investing.com - Investing.com UK

Thu, 25 Jan 2024
Where Will Addex Therapeutics Ltd - ADR (ADXN) Stock Go Next After It Has Gained 50.07% in a Week? - InvestorsObserver

Mon, 08 Jan 2024
Should You Hold Addex Therapeutics Ltd - ADR (ADXN) Stock Monday Morning? - InvestorsObserver

Thu, 04 Jan 2024
Addex to Present at Biotech Showcase™ 2024 - Yahoo Finance

Fri, 01 Dec 2023
Timothy Dyer Bought 71% More Shares In Addex Therapeutics - Yahoo Finance

Fri, 06 Oct 2023
Addex Announces Plan to Implement ADS Ratio Change - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 1 (M)
Shares Float 48 (M)
Held by Insiders 0 (%)
Held by Institutions 18.4 (%)
Shares Short 9 (K)
Shares Short P.Month 2 (K)
Stock Financials
EPS -20.33
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.05
Profit Margin 0 %
Operating Margin -805.8 %
Return on Assets (ttm) -75.5 %
Return on Equity (ttm) -190.9 %
Qtrly Rev. Growth -20.8 %
Gross Profit (p.s.) 0
Sales Per Share 1.94
EBITDA (p.s.) -10.66
Qtrly Earnings Growth 0 %
Operating Cash Flow -10 (M)
Levered Free Cash Flow -6 (M)
Stock Valuations
PE Ratio -0.48
PEG Ratio 0
Price to Book value 193.39
Price to Sales 4.97
Price to Cash Flow -0.99
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android